UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 28, 2017

 

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   001-37769   N/A
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

222 Third Street, Suite 2241

Cambridge, Massachusetts

  02142
(Address of principal executive offices)   (Zip Code)

 

(617) 830-3031

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

As previously reported, Variation Biotechnologies (US), Inc. (the “Borrower”), a subsidiary of VBI Vaccines, Inc. (the “Company”), the guarantors on the signature pages thereto (the “Guarantors”), and Perceptive Credit Holdings, L.P. (“Perceptive”) are parties to that certain Amended and Restated Credit Agreement and Guaranty, dated December 6, 2016, (the “Existing Credit Agreement”). The Existing Credit Agreement provided that the Company is required have raised at least $15,000,000 in cash common equity upon terms and conditions reasonably satisfactory to Perceptive on or before September 30, 2017 (the “Milestone”).

 

On September 28, 2017 the Borrower, the Company, the Guarantors and Perceptive entered into an Amendment to Amended and Restated Credit Agreement and Guaranty (the “Amendment”), to modify the date that the Company is required to have achieved the Milestone from September 30, 2017 to November 30, 2017.

 

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
10.1   Amendment to Amended and Restated Credit Agreement and Guaranty

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VBI Vaccines Inc.
     
Date:  October 2, 2017 By: /s/ Jeff Baxter
    Jeff Baxter
    President and Chief Executive Officer

 

 
 

 

 

Execution Version

 

AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND

GUARANTY

 

This AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND

 

GUARANTY, dated as of September 28, 2017 (this “ Amendment ”), is made by and among VARIATION BIOTECHNOLOGIES (US), INC., a Delaware corporation (the “ Borrower ”), the Guarantors identified under the caption “GUARANTORS” on the signature pages hereto, and Perceptive Credit Holdings, LP, a Delaware limited partnership (the “ Lender ”). Unless otherwise defined herein or the context otherwise requires, terms used in this Amendment, including its preamble and recitals, have the meanings provided in the Credit Agreement (defined below).

 

W I T N E S S E T H :

 

WHEREAS, the Borrower, the Guarantors and the Lender have entered into that certain Amended and Restated Credit Agreement and Guaranty, dated as of December 6, 2016 (the “ Credit Agreement ”);

 

WHEREAS, the Borrower has requested that the Lender agree to certain amendments and modifications to the Credit Agreement as further described herein; and

 

WHEREAS, the Lender is willing to agree to such amendments and modifications subject to the terms and conditions set forth herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE I

DEFINITIONS

 

SECTION 1.1. Certain Terms . The following terms (whether or not underscored) when used in this Amendment, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

Amendment ” is defined in the preamble.

 

Amendment Effective Date ” is defined in Article III.

 

Borrower ” is defined in the preamble.

 

Credit Agreement ” is defined in first recital.

 

Lender ” is defined in the preamble.

 

1
 

 

ARTICLE II

AMENDMENTS TO CREDIT AGREEMENT

 

The provisions of the Credit Agreement referred to below are hereby amended in accordance with this Article II . Except as expressly so amended, the parties hereto expressly acknowledge and agree that all other terms and provisions of the Credit Agreement and each other Loan Document shall continue in full force and effect in accordance with its terms.

 

SECTION 2.1. Amendment to Section 7.18 . Effective on (and subject to the occurrence of) the Amendment Effective Date, Section 7.18(a) of the Credit Agreement is hereby amended by replacing the reference to “September 30, 2017” with “November 30, 2017.”

 

ARTICLE III

CONDITIONS PRECEDENT

 

This Amendment shall become effective upon, and shall be subject to, the prior or simultaneous satisfaction of each of the following conditions in a manner reasonably satisfactory to the Lender (the date when all such conditions are so satisfied being the “ Amendment Effective Date ”):

 

SECTION 3.1. Counterparts . The Lender shall have received counterparts of this Amendment executed on behalf of the Borrower, the Guarantors, and the Lender.

 

SECTION 3.2. Costs and Expenses, etc . The Lender shall have received all fees, costs and expenses due and payable pursuant to Section 11.3 of the Credit Agreement (including without limitation the reasonable fees and expenses of Morrison & Foerster LLP, counsel to the Lender), if then invoiced, together with any other fees separately agreed to by the Borrower and the Lender.

 

SECTION 3.3. Amendment Effective Date Certificate . The Lender shall have received a certificate, dated as of the Amendment Effective Date and in form and substance satisfactory to the Lender, duly executed and delivered by an Authorized Officer of the Borrower, in which certificate the Borrower shall certify, represent and warrant that, at the time such certificate is delivered, (i) all statements, representations and warranties set forth in Article IV below are true and correct immediately before and immediately after giving effect to the Amendment Effective Date, and (ii) all of the conditions set forth in this Article III have been satisfied.

 

SECTION 3.4. Satisfactory Legal Form, etc . All legal matters incident to the effectiveness of this Amendment shall be reasonably satisfactory to the Lender and its counsel.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES

 

To induce the Lender to enter into this Amendment, each Loan Party represents and warrants to the Lender as set forth below.

 

SECTION 4.1. Validity, etc . This Amendment and the Credit Agreement (after giving effect to this Amendment) each constitutes the legal, valid and binding obligation of each Loan Party, enforceable in accordance with its respective terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.

 

2
 

 

SECTION 4.2. Representations and Warranties, etc . Immediately prior to, and immediately after giving effect to, this Amendment the following statements shall be true and correct:

 

(a)       the representations and warranties set forth in each Loan Document (as defined in the Credit Agreement) shall, in each case, be true and correct in all respects with the same effect as if then made (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date); and

 

(b)      no Default (as defined in the Credit Agreement) shall have then occurred and be continuing.

 

ARTICLE V

CONFIRMATION

 

SECTION 5.1. Guarantees, Security Interest, Continued Effectiveness . Each Loan Party hereby consents to the modifications made to the Loan Documents pursuant to this Amendment and hereby agrees that, after giving effect to this Amendment, each Loan Document to which it is a party is and shall continue to be in full force and effect and the same are hereby ratified in all respects, except that upon the occurrence of the Amendment Effective Date, all references in such Loan Documents to the “Credit Agreement”, “Loan Documents”, “thereunder”, “thereof”, or words of similar import shall mean the Credit Agreement and the other Loan Documents, as amended or otherwise modified by this Amendment.

 

SECTION 5.2. Validity, etc . Each Loan Party hereby represents and warrants, as of the Amendment Effective Date, that immediately after giving effect to this Amendment, each Loan Document, in each case as modified by this Amendment (where applicable and whether directly or indirectly), to which it is a party continues to be a legal, valid and binding obligation of such Loan Party, enforceable against such Person in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing.

 

ARTICLE VI

MISCELLANEOUS

 

SECTION 6.1. Cross-References . References in this Amendment to any Article or Section are, unless otherwise specified, to such Article or Section of this Amendment.

 

SECTION 6.2. Loan Document Pursuant to Credit Agreement . This Amendment is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated therein) be construed, administered and applied in accordance with all of the terms and provisions of the Credit Agreement, as amended hereby.

 

3
 

 

SECTION 6.3. Successors and Assigns . This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

SECTION 6.4. Counterparts . This Amendment may be executed by the parties hereto in several counterparts, each of which when executed and delivered shall be an original and all of which shall constitute together but one and the same agreement. Delivery of an executed counterpart of a signature page to this Amendment by facsimile (or other electronic transmission) shall be effective as delivery of a manually executed counterpart of this Amendment.

 

SECTION 6.5. Governing Law . THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK.

 

SECTION 6.6. Full Force and Effect; Limited Amendment . Except as expressly amended hereby, the Loan Parties each jointly and severally agree that all of the representations, warranties, terms, covenants, conditions and other provisions of the Credit Agreement and the other Loan Documents shall remain unchanged and shall continue to be, and shall remain, in full force and effect in accordance with their respective terms. The amendments and other waivers and modifications set forth in this Amendment shall be limited precisely as provided for herein to the provisions expressly amended herein or otherwise modified or waived hereby and shall not be deemed to be an amendment to, waiver of, consent to or modification of any other term or provision of the Credit Agreement or any other Loan Document or of any transaction or further or future action on the part of any Credit Party which would require the consent of the Lenders under the Credit Agreement or any of the Loan Documents.

 

SECTION 6.7. No Waiver . This Amendment is not, and shall not be deemed to be, a waiver of or a consent to any Event of Default, event with which the giving of notice or lapse of time or both may result in an Event of Default, or other non-compliance now existing or hereafter arising under the Credit Agreement and the other Loan Documents.

 

[Signature pages to follow]

 

4
 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and delivered as of the day and year first above written.

 

  BORROWER
   
  VARIATION BIOTECHNOLOGIES (US), INC.
                                    
  By: /s/ Jeff Baxter  
  Name: Jeff Baxter
  Title: Chief Executive Officer
     
  GUARANTORS
   
  SCIVAC LTD
     
  By: /s/ Jeff Baxter  
  Name: Jeff Baxter
  By: Chief Executive Officer
     
  VARIATION BIOTECHNOLOGIES INC.
     
  By: /s/ Jeff Baxter  
  Name: Jeff Baxter
  Title: Chief Executive Officer
     
  VBI VACCINES INC.
     
  By: /s/ Jeff Baxter  
  Name: Jeff Baxter
  Title: Chief Executive Officer
     
  VBI VACCINES (DELAWARE) INC.
     
  By: /s/ Jeff Baxter  
  Name: Jeff Baxter
  Title: Chief Executive Officer
     
  LENDER
   
  PERCEPTIVE CREDIT HOLDINGS, LP
  By Perceptive Credit Opportunities GP, LLC, its general partner
     
  By: /s/ Sandeep Dixit  
  Name: Sandeep Dixit
  Title: Chief Credit Officer
     
  By: /s/ Sam Chawla  
  Name: Sam Chawla
  Title: Portfolio Manager

 

[Signature Page to Amendment]